One imaging platform.
Multiple clinical markets.
MLI® of human skin cancer.
Executive Summary
illumiSonics has developed a proprietary imaging platform, MLI®, that extracts rich molecular information from unstained tissue without consuming the sample. The technology enables virtual histology, virtual IHC, multimodal biomarker generation, and novel diagnostic classifiers from a single scan.
Unlike software-only approaches, the company’s differentiation is rooted in proprietary imaging physics protected by 40+ patents across 12 patent families. The platform supports multiple commercialization pathways across pathology, intraoperative imaging, and ophthalmology.
40+ patents
56+ publications
12+ patent families
MLI® Cancer Diagnostics
98%+
Cancer versus Benign Diagnostic Agreement with Gold Standard
Demonstrated feasibility for fully digital AI powered diagnostic workflow in partnership with Modella AI
Clinical feasibility study under way with Sunnybrook Research Institute funded by INOVAIT Canada
Key Markets
$5B
TAM
Targeting Pathology with AID
Our Advanced Imaging Device (AID) replaces destructive, tissue-consuming pathology workflows with multiplexed AI analysis on a single unstained FFPE slide. This preserves scarce tissue for downstream assays and accelerates novel biomarker development. Targeting pharma and CAP/CLIA labs, the platform is commercially derisked: it is actively generating revenue via our Slide Scanning as a Service (SSaaS) model, securing device pre-orders, and driving four proprietary in-house diagnostic programs.
$500M
TAM
Targeting Mohs Surgery with SID
Our Surgical Imaging Device (SID) targets an uncontested fresh-tissue market. By replacing slow frozen sections with near-instant MLI® scans, the SID dramatically increases Mohs clinic throughput and reduces repeat surgeries. Highly capital-efficient, the SID leverages the exact same validated hardware architecture as our AID, with a clinical feasibility trial scheduled this year with to unlock this high-value surgical market.
Why now?
MLI® has transitioned from hardware development to commercial execution. Invest today to help us scale a derisked, revenue-generating platform.
AID
Clinical validation complete
Commercial prototypes complete
Production pre-orders happening now
Customer traction in slide scanning as a service
SID
Clinical partners identified
Initial customers identified
Market analysis complete
Shared proven architecture from pathology device
Invest with illumiSonics Inc.
We are currently opening conversations with strategic investors to accelerate the commercial rollout of our AID and SID platforms. Connect with us today to explore available opportunities.
Dr. John Mackey MD, FRCPC, FCAHS
Chief Executive Officer of illumiSonics Inc.
Medical Oncologist and Professor Emeritus of Oncology at the University of Alberta
✉️ john.mackey@illumisonics.com